Abstract
A series of pyrido[2,3-d]pyrimidine derivatives were designed and synthesized based on known CC chemokine receptor 4 (CCR4) antagonists. The activities of all the newly synthesized compounds were evaluated using a chemotaxis inhibition assay. Compound 6b was proven to be a potent CCR4 antagonist that can block cell chemotaxis induced by macrophage-derived chemokine (MDC), thymus and activation regulated chemokine (TARC), and CKLF1, the natural ligands of CCR4. In addition, compound 6b is more effective than budesonide in the murine rhinitis model. The intravenous injection LD50 of compound 6b is 175 mg/kg and the oral LD50 is greater than 2,000 mg/kg.
Highlights
CC chemokine receptor 4 (CCR4) is a pivotal factor in the development of allergic inflammations, such as asthma, dermatitis, and rhinitis [1]
Through the chemotaxis of the three ligands of CCR4, the Th2 cells are attracted to the sites of allergic inflammation
The number of macrophage-derived chemokine (MDC), thymus and activation regulated chemokine (TARC), and CCR4-expressing T cells is increased in asthmatic lungs and airways
Summary
CC chemokine receptor 4 (CCR4) is a pivotal factor in the development of allergic inflammations, such as asthma, dermatitis, and rhinitis [1]. It consists of a seven-transmembrane G-protein-coupled receptor that is selectively expressed on Th2 cell membranes. The number of MDC, TARC, and CCR4-expressing T cells is increased in asthmatic lungs and airways. The CCR4 blocking antibody attenuates airway eosinophilia and goblet cell hyperplasia and diminishes IgE synthesis and bronchial hyperreactivity [5]. Like the CCR4 antibody, the special Ab against TARC and MDC can reduce airway eosinophilia and hyperresponsiveness in asthmatic mice elicited by OVA [6,7].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
